Effects of the prophylactic use of escitalopram on the prognosis and the plasma copeptin level in patients with acute cerebral infarction

Brazilian Journal of Medical and Biological Research

Volumn 53, Issue 11, 2020, Pages 1-6

  Cao, Jin Xia ^a   Liu, Li ^a   Sun, Yun Tao ^a   Zeng, Qing Hong ^a   Wang, Yan ^a   Chen, Jie Chun ^a  

^a Second People Hospital of Lianyungang   (China)

Author keywords

Acute cerebral infarction; Copeptin; Escitalopram; Prognosis; Stroke

Indexed keywords

COPEPTIN; ESCITALOPRAM; MICRORNA; PLACEBO; WARFARIN; ZOLPIDEM; CITALOPRAM;

ADULT; APHASIA; ARTICLE; BARTHEL INDEX; BLURRED VISION; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DROWSINESS; DSM-IV; ECHOGRAPHY; ELECTROCARDIOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HAMILTON DEPRESSION RATING SCALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PHYSIOTHERAPY; POST-STROKE DEPRESSION; PROGNOSIS; PROPHYLAXIS; SECONDARY PREVENTION; XEROSTOMIA; ACUTE DISEASE; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ACUTE DISEASE; BRAIN ISCHEMIA; CEREBRAL INFARCTION; CITALOPRAM; HUMANS; STROKE; UNITED STATES;

EID: 85092886946     PISSN: None     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20208930     Document Type: Article

References (20)

1. Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2013; 381: 1987–2015, doi: 10.1016/S0140-6736(13)61097-1
2. Lapergue B, Blanc R, Gory B, Labreuche J, Duhamel A, Marnat G, et al. Effect of endovascular contact aspiration vs stent retriever on revascularization in patients with acute ischemic stroke and large vessel occlusion: the ASTER randomized clinical trial. JAMA 2017; 318: 443–452, doi: 10.1001/jama.2017.9644
3. Le Friec A, Salabert AS, Davoust C, Demain B, Vieu C, Vaysse L, et al. Enhancing plasticity of the central nervous system: drugs, stem cell therapy, and neuro-implants. Neural Plast 2017; 2017: 2545736, doi: 10.1155/2017/2545736
4. Siepmann T, Penzlin AI, Kepplinger J, Illigens BM, Weidner K, Reichmann H, et al. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. Brain Behav 2015; 5: e00373, doi: 10.1002/brb3.373
5. Pinto CB, Saleh Velez FG, Lopes F, de Toledo Piza PV, Dipietro L, Wang QM, et al. SSRI and motor recovery in stroke: reestablishment of inhibitory neural network tonus. Front Neurosci 2017; 11: 637, doi: 10.3389/fnins.2017. 00637
6. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011; 10: 123–130, doi: 10.1016/S1474-4422(10)70314-8
7. Robinson RG, Jorge RE. Post-stroke depression: a review. Am J Psychiatry 2016; 173: 221–231, doi: 10.1176/appi. ajp.2015.15030363
8. Ruhé HG, Khoenkhoen SJ, Ottenhof KW, Koeter MW, Mocking RJ, Schene AH. Longitudinal effects of the SSRI paroxetine on salivary cortisol in major depressive disorder. Psychoneuroendocrinology 2015; 52: 261–271, doi: 10.1016/j.psyneuen.2014.10.024
9. Barreca T, Gandolfo C, Corsini G, Del Sette M, Cataldi A, Rolandi E, et al. Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. Cerebrovasc Dis 2001; 11: 113–118, doi: 10.1159/000047622
10. Zeynalov E, Jones SM. Recent advances and future directions in preclinical research of arginine-vasopressin (AVP) receptor blocker conivaptan in the context of stroke. Neural Regen Res 2016; 11: 392–393, doi: 10.4103/1673-5374.179038
11. Fernandez SJ, Barakat I, Ziogas J, Frugier T, Stylli SS, Laidlaw JD, et al. Association of copeptin, a surrogate marker of arginine vasopressin, with cerebral vasospasm and delayed ischemic neurologic deficit after aneurysmal subarachnoid hemorrhage. J Neurosurg 2018: 1–7, doi: 10.3171/2017.10.JNS17795
12. Katan M, Fluri F, Morgenthaler NG, Schuetz P, Zweifel C, Bingisser R, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009; 66: 799–808, doi: 10.1002/ana.21783
13. Tu WJ, Ma GZ, Ni Y, Hu XS, Luo DZ, Zeng XW, et al. Copeptin and NT-proBNP for prediction of all-cause and cardiovascular death in ischemic stroke. Neurology 2017; 88: 1899–1905, doi: 10.1212/WNL.000000000000 3937
14. Dong X, Tao DB, Wang YX, Cao H, Xu YS, Wang QY. Plasma copeptin levels in Chinese patients with acute ischemic stroke: a preliminary study. Neurol Sci 2013; 34: 1591-1595, doi: 10.1007/s10072-013-1291-2
15. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early manage-ment of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Associa-tion/American Stroke Association. Stroke 2013; 44: 870-947, doi: 10.1161/STR.0b013e318284056a
16. Chen H, Liu Y, Huang G, Zhu J, Feng W, He J. Association between vitamin D status and cognitive impairment in acute ischemic stroke patients: a prospective cohort study. Clin Interv Aging 2018; 13: 2503–2509, doi: 10.2147/CIA. S187142
17. Ng KL, Gibson EM, Hubbard R, Yang J, Caffo B, O’Brien RJ, et al. Fluoxetine maintains a state of heightened responsiveness to motor training early after stroke in a mouse model. Stroke 2015; 46: 2951–2960, doi: 10.1161/STROKEAHA. 115.010471
18. Robinson RG, Jorge RE, Moser DJ, Acion L, Solodkin A, Small SL, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA 2008; 299: 2391–2400, doi: 10.1001/jama.299.20.2391
19. Ronaldson A, Carvalho LA, Kostich K, Lazzarino AI, Urbanova L, Steptoe A. The effects of six-day SSRI administration on diurnal cortisol secretion in healthy volunteers. Psychopharmacology (Berl) 2018; 235: 3415– 3422.
20. Buhl CS, Stødkilde-Jørgensen H, Videbech P, Vaag A, Møller N, Lund S, et al. Escitalopram ameliorates hypercortisolemia and insulin resistance in low birth weight men with limbic brain alterations. J Clin Endocri-nol Metab 2018; 103: 115–124, doi: 10.1210/jc.2017-01438